#Denmark #Lundbeck #Valby #Vyepti #Rexulti

Lundbeck's Strong Financial Performance in 2025

Lundbeck's total revenue experienced a significant increase, reporting a 14% growth at constant exchange rates (CER) for the first nine months of 2025. This impressive growth, which translates to a revenue of DKK 18,537 million, can largely be attributed to robust performances in both the U.S. and European markets. The company reported strong sales for its strategic brands, resulting in a remarkable 20% CER growth and accounting for 77% of its total revenue, establishing Lundbeck as a key player in the biopharmaceutical sector focused on brain health.

Key Drivers of Revenue Growth

The revenue uptick was largely driven by Lundbeck's strategic medications:

• - Rexulti® generated a revenue of DKK 4,695 million, marking a 26% increase at CER.
• - Vyepti®, for migraine prevention, saw a shocking growth of 57% at CER, resulting in DKK 3,254 million in revenue.
• - Other notable contributions came from Brintellix®, which despite facing some challenges, reached DKK 3,453 million, and the Abilify® LAI franchise, accumulating DKK 2,858 million.

This surge in revenue is indicative of Lundbeck's successful capital reallocation strategy, which has allowed for investments that drive both immediate performance and long-term growth. During the quarter, Lundbeck's EBITDA surged to DKK 6,207 million, showing an impressive 39% increase at CER.

Future Outlook and Financial Guidance

As of November 11, 2025, Lundbeck announced an upward revision in its financial guidance for the year. Revenue growth is now projected to sit between 13% and 14% at CER, an increase from the initial forecast of 11% to 13%. Similarly, the adjusted EBITDA growth outlook has been raised to between 22% and 25% at CER.

Lundbeck's President and CEO, Charl van Zyl, emphasized that this performance stems from their focused investments, particularly in Vyepti® and Rexulti®. The implementation of a new commercial operating model in 27 markets aims to enhance operational efficiency and unlock further growth potential. This model will enable Lundbeck to reallocate capital efficiently and fuel advancements in new product pipelines while maximizing existing portfolios.

Strategic Collaborations and Innovations

The quarter also bore witness to Lundbeck's collaborations aimed at boosting its innovation efforts within the neuroscience space. Notably, the partnership with OpenAI focuses on harnessing advanced AI tools to improve operational efficiencies and discovery processes throughout the value chain.

Additionally, the collaboration with Contera Pharma will expedite the research and development of innovative oligonucleotide-based treatments for severe neurological conditions, reflecting Lundbeck's dedication to addressing unmet medical needs.

Recent Developments and Regulatory Advancements

In other significant news, Lundbeck's investigational drug bexicaserin was awarded Breakthrough Therapy Designation by China's Center for Drug Evaluation for its treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs). This designation highlights the potential of bexicaserin to offer transformative treatment options for patients facing critical healthcare challenges.

With five to six mid to late-stage pipeline assets on track by 2026, Lundbeck is well-positioned not only to maintain but to expand its footprint in the neuroscience market. Innovations such as amlenetug, also presented at major medical congresses, promise to further their commitment to providing effective solutions for patients worldwide.

Conclusion

Lundbeck’s recent performance illustrates a robust trajectory in revenue and strategic efforts, underpinned by innovative therapies and a strong operational foundation geared toward future growth. The company aims to continue building on this momentum, focusing on sustainable growth and ongoing enhancements within the neuroscience field. With Lundbeck at the helm of innovation in brain health, patients around the globe can look forward to better therapeutic options in the years to come.